The Congress will focus on key clinical topics in the management of genitourinary malignancies, including prognostic/predictive markers in care, proactive methods to mitigate predictable treatment-related side effects, optimal use of chemotherapeutic strategies, androgen-deprivation therapies, targeted therapies, radiopharmaceuticals, and immunotherapies, as well as explore emerging data on various combinations and sequences of treatment strategies currently undergoing clinical trial evaluation. The Congress continues to evolve and expand its coverage of some of the fastest moving areas in the management of genitourinary malignancies. To that end, there will be an expanded focus on bladder cancer and renal cell carcinoma, given recent practice-changing developments that continue to alter the therapeutic landscape in these fields of care. Key questions concerning the application of landmark clinical trial data on emerging targeted and immunotherapeutic options, as well as the application of emerging biomarkers for these tumors, will be answered during expanded sessions on these topics.
This year’s New York GU™ meeting is not to be missed! The activity is sure to continue its legacy and tradition of providing clinicians with the valuable knowledge and confidence to maintain state-of-the-art care and optimize outcomes for patients with genitourinary malignancies.
This educational activity is directed toward medical, surgical, and radiation oncologists involved in the treatment of patients with genitourinary (GU) malignancies. Urologists, fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, nuclear medicine physicians, and other healthcare professionals interested in the treatment of GU malignancies may also participate.
At the conclusion of this activity, participants should be better prepared to:
Daniel P. Petrylak, MD
Professor of Medicine, Medical Oncology
Director, Prostate and GU Medical Oncology
Director, Prostate Cancer Translational Research Program
Yale Cancer Center
New Haven, CT
Leonard G. Gomella, MD, FACS
The Bernard W. Godwin Professor of Prostate Cancer
Chairman, Department of Urology
Associate Director, Jefferson Kimmel Cancer Center
Clinical Director Jefferson Kimmel Cancer Center Network
Thomas Jefferson University
Dec 31, 2018
Medical Crossfire®: Defining New Roles for the Application of PARP Inhibition Strategies in Multiple Tumor Types
Dec 31, 2018
Dec 31, 2018